Angiotensin 1-7: The Body's Regenerative Counterbalance

Imagine a natural counterbalance within your body, actively working to keep things in harmony, particularly when faced with cellular stress or damage. This isn't science fiction; it's the fascinating reality of Angiotensin 1-7 (Ang-(1-7)), a peptide that's rapidly gaining attention in regenerative research. While its better-known cousin, Angiotensin II (Ang II), often takes the spotlight for its role in vasoconstriction and disease, Ang-(1-7) plays a crucial, often opposing, role. Researchers are uncovering its ability to temper inflammation, support muscle repair, and even impact processes linked to metabolic disorders. The implications are profound, hinting at new avenues for understanding and potentially addressing a range of complex conditions.

What is Angiotensin 1-7?

Angiotensin 1-7 is a key component of the intricate Renin-Angiotensin System (RAS), a complex network of enzymes, peptides, and receptors that regulates blood pressure, fluid balance, and tissue health. Historically, Ang II was considered the primary effector molecule of the RAS, largely associated with vasoconstriction and pro-inflammatory effects (PMID 15962175, PMID 27456244). However, Ang-(1-7) has emerged as a distinct, biologically active peptide, often acting as a counter-regulatory force to Ang II (PMID 15962175, PMID 27121991, PMID 26788046).

This peptide can be formed from Ang II or directly from Angiotensin I (Ang I) through enzymatic pathways involving enzymes like angiotensin-converting enzyme 2 (ACE2). The biological relevance of Ang-(1-7) was further solidified with the identification of its specific receptor, the G-protein-coupled receptor Mas (PMID 15962175). Its presence and actions are particularly notable in vital organs like the heart and blood vessels (PMID 15962175).

Why researchers are excited

The excitement surrounding Ang-(1-7) stems from its potential to counteract several detrimental effects typically associated with Ang II, positioning it as a peptide with broad therapeutic interest (PMID 27121991, PMID 26788046). It's recognized for its anti-inflammatory, antifibrotic, and metabolic regulatory effects (PMID 40955298). Review articles highlight a plethora of potential applications, supported by experimental evidence and numerous patents (PMID 27121991). The variety of clinical trials involving Ang-(1-7) further underscores its perceived potential, spanning areas from cardiovascular health and hematology to transplantation and even cancer treatment (PMID 27121991).

One of its most compelling attributes is its ability to modulate various physiological processes. For instance, it's been shown to improve lipid profiles and insulin resistance by influencing insulin actions, alongside reducing inflammation, particularly in the context of metabolic disorders like obesity and type 2 diabetes (PMID 30905634). Furthermore, its role as a vasodilator, achieved by activating the nitric oxide pathway in the endothelium, sets it apart from Ang II (PMID 27456244).

What the studies found

Research has illuminated several key actions of Ang-(1-7) across different models:

| Study | Model | Key finding | PMID | | :----------------------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------ | | Angiotensin-(1-7) improves skeletal muscle regeneration | C2C12 cells (in vitro); C57BL/6 WT male mice (in vivo) | In C2C12 cells, Ang-(1-7) increased myotube diameter and protein levels of myogenin and myosin heavy chain. In mice, Ang-(1-7) enhanced regeneration, promoting larger new muscle fiber diameter and elevating embryonic myosin and myogenin protein levels after injury. | 38112612 | | Angiotensin-(1-7), Adipokines and Inflammation | Review of studies | Increased activation of the ACE2/Ang-(1-7)/MasR arm can revert and prevent local and systemic dysfunctions, improving lipid profiles and insulin resistance by modulating insulin actions and reducing inflammation, especially in metabolic disorders. | 30905634 | | Angiotensin-(1-7) Inhibits Angiogenesis and Alleviates Joint Damage in CIA Mice via the Hippo-YAP Pathway | Human umbilical vein endothelial cells (HUVECs); Collagen-induced arthritis (CIA) mice | Ang-(1-7) reduced systemic inflammation, inhibited synovial angiogenesis, and attenuated joint damage (hyperplasia, inflammation, cartilage destruction) in CIA mice. It inhibited TNF-α-induced HUVEC proliferation, migration, and tube formation by modulating the Hippo-YAP pathway. | 40955298 | | Therapeutic uses for Angiotensin-(1-7) | Review of patents and clinical trials | A plethora of therapeutic uses for Ang-(1-7) are claimed and supported by experimental evidence in patent documents and applications, with clinical studies across cancer, cardiovascular, hematological, transplantation, and surgical/medical procedures. | 27121991 | | Angiotensin-(1-7): new perspectives in atherosclerosis treatment | Review of studies | Ang-(1-7) is protective against cardiovascular disease, reducing smooth muscle cell proliferation and migration, improving endothelial function, and regulating lipid metabolism, thereby inhibiting atherosclerotic lesions and increasing plaque stability. | 26788046 |

One of the most striking recent findings relates to its role in skeletal muscle. In an *in vitro* study using C2C12 cells, Ang-(1-7) notably increased the diameter of myotubes and boosted the protein levels of myogenin and myosin heavy chain during differentiation (PMID 38112612). Taking this to an *in vivo* model, male mice (16-18 weeks old) with muscle injury saw enhanced regeneration with Ang-(1-7) administration. This was evidenced by a larger diameter of new muscle fibers and elevated levels of embryonic myosin and myogenin proteins (PMID 38112612).

Beyond muscle, Ang-(1-7) demonstrates significant anti-inflammatory and metabolic effects. It has been shown to interact with and regulate adipokines, acting as an adipokine itself, to modulate body homeostasis (PMID 30905634). Specifically, increased activation of the ACE2/Ang-(1-7)/MasR pathway can reverse and prevent local and systemic dysfunctions, improving lipid profiles and insulin resistance by modulating insulin actions, all while reducing inflammation, particularly in the context of obesity and type 2 diabetes (PMID 30905634).

Its anti-inflammatory and antifibrotic properties extend to joint health. In a collagen-induced arthritis (CIA) model in mice, Ang-(1-7) treatment significantly reduced systemic inflammation, inhibited synovial angiogenesis (the formation of new blood vessels), and alleviated joint damage, including synovial hyperplasia, inflammatory cell infiltration, and cartilage destruction. Mechanistically, it was shown to inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) by modulating the Hippo-YAP pathway (PMID 40955298).

In cardiovascular health, Ang-(1-7) is recognized as a protective agent against conditions like atherosclerosis. It has been found to reduce smooth muscle cell proliferation and migration, improve endothelial function, and regulate lipid metabolism, which collectively lead to the inhibition of atherosclerotic lesions and increased plaque stability (PMID 26788046). It also acts as a vasodilator, promoting nitric oxide release from the endothelium (PMID 27456244, PMID 29541937).

How it's thought to work

Angiotensin 1-7 exerts its effects primarily by counteracting the more deleterious actions of Angiotensin II within the Renin-Angiotensin System (RAS) (PMID 15962175, PMID 27121991). It typically functions through its specific receptor, the G-protein-coupled receptor Mas (PMID 15962175). This interaction initiates pathways that often oppose those activated by Ang II, leading to a balancing effect within the body.

For instance, Ang-(1-7) acts as a vasodilator by activating the nitric oxide pathway in the endothelium, a mechanism that contrasts with Ang II's vasoconstrictive properties (PMID 27456244). In metabolic contexts, its action via the ACE2/Ang-(1-7)/MasR arm helps improve lipid profiles and insulin resistance by modulating insulin actions, reducing inflammation (PMID 30905634).

In the context of muscle regeneration, Ang-(1-7) promotes differentiation in C2C12 cells and enhances muscle fiber growth *in vitro* and *in vivo* (PMID 38112612). For joint health and angiogenesis, Ang-(1-7) was found to modulate the Hippo-YAP pathway, leading to inhibition of YAP activation and suppression of downstream targets like hypoxia-inducible factor-1 (HIF-1), vascular endothelial growth factor (VEGF), and VEGF receptor 2 (VEGFR2). This ultimately suppresses endothelial cell activity, attenuating angiogenesis, inflammation, and joint damage in mice (PMID 40955298).

The catch: what we still don't know

While the research on Angiotensin 1-7 is undeniably promising, it's still in relatively early stages, especially concerning its broad applicability in human health. Many of the impressive findings discussed here are from *in vitro* (cell culture) or animal models, specifically mice (PMID 38112612, PMID 40955298). While clinical trials are underway in various areas, the specifics of their outcomes and comprehensive human data are not detailed in these abstracts (PMID 27121991).

One significant challenge highlighted is the pharmacokinetic properties of Ang-(1-7), which have restricted its clinical application. Researchers are actively working on identifying stabilized compounds, such as more stable analogues and specific delivery systems, to overcome these limitations and enable broader clinical use (PMID 26788046).

Furthermore, while Ang-(1-7) has shown beneficial effects in various experimental models of hypertension, fewer studies have focused on its effects in experimental models of atherosclerosis (PMID 29541937). The full spectrum of its interactions and long-term effects, especially in complex human systems, remains an area for continued exploration.

Keep exploring

Angiotensin 1-7 represents a captivating area of regenerative research, offering a glimpse into the body's intrinsic mechanisms for repair and balance. The journey from initial discovery to clinical application is long, but the early findings paint a vivid picture of potential. As science continues to unravel the complexities of peptides like Ang-(1-7), we move closer to a deeper understanding of health and disease.

Want to dive deeper into the world of peptides? Browse our A–Z protocols for more insights, compare compounds, and stay updated on the latest breakthroughs. Don't forget to share this article with fellow enthusiasts and contribute to the conversation!

Sources

* Angiotensin-(1-7), Adipokines and Inflammation. Metabolism: clinical and experimental, 2019. https://pubmed.ncbi.nlm.nih.gov/30905634 * Therapeutic uses for Angiotensin-(1-7). Expert opinion on therapeutic patents, 2016. https://pubmed.ncbi.nlm.nih.gov/27121991 * Angiotensin-(1-7) improves skeletal muscle regeneration. European journal of translational myology, 2023. https://pubmed.ncbi.nlm.nih.gov/38112612 * Cardiovascular actions of angiotensin-(1-7). Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2005. https://pubmed.ncbi.nlm.nih.gov/15962175 * Angiotensin (1-7) and Alamandine: Similarities and differences. Pharmacological research, 2016. https://pubmed.ncbi.nlm.nih.gov/27456244 * Angiotensin-(1-7) Inhibits Angiogenesis and Alleviates Joint Damage in CIA Mice via the Hippo-YAP Pathway. Journal of inflammation research, 2025. https://pubmed.ncbi.nlm.nih.gov/40955298 * Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis. Current hypertension reports, 2018. https://pubmed.ncbi.nlm.nih.gov/29541937 * Angiotensin-(1-7): new perspectives in atherosclerosis treatment. Journal of geriatric cardiology : JGC, 2015. https://pubmed.ncbi.nlm.nih.gov/26788046